Pregled bibliografske jedinice broj: 1047581
Mergers And Acquisitions As A Consequence Of Declining Innovation Productivity In Pharmaceuticals: Evidence From Croatia
Mergers And Acquisitions As A Consequence Of Declining Innovation Productivity In Pharmaceuticals: Evidence From Croatia // Mednarodno inovativno poslovanje, 12 (2020), 1; 1-8 doi:10.32015/JIBM/2020-12-1-1. (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1047581 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Mergers And Acquisitions As A Consequence Of
Declining Innovation Productivity In
Pharmaceuticals: Evidence From Croatia
Autori
Mance, Davor ; Vretenar, Nenad ; Gudelj, Antonia
Izvornik
Mednarodno inovativno poslovanje (1855-6175) 12
(2020), 1;
1-8
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
M&As, pharmaceutical industry, R&D
Sažetak
Declining productivity of pharmaceutical innovation resulted in an increased number of mergers & acquisitions in the pharmaceutical industry. Increased investments into research & development lack the resulting increases in patentable new substances. As a result, the once market leaders are not buying their followers, but the generics producers are buying unsuccessful innovators. We show the case of Pliva: once regional pharma leader that declined into a generics producer's subsidiary. The Pliva sought new ideas by acquiring several research centres. After these acquisitions produced no visible results, the company itself was a target, first by another unsuccessful R&D based company and lastly, by a successful generics producer.
Izvorni jezik
Engleski
Znanstvena područja
Ekonomija
POVEZANOST RADA
Ustanove:
Ekonomski fakultet, Rijeka
